**Reply to Leon et al.**

Samuele Cortese 1-5 , David Coghill 6,7,8

1 Center for Innovation in Mental Health, Academic Unit of Psychology, University of

Southampton, UK, SO17 1BJ

2 Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of

Southampton, UK, SO17 1BJ

3 Solent NHS Trust, Southampton, UK, SO19 8BR

4 New York University Child Study Center, New York, NY, USA, 10016

5 Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham,

Nottingham, UK, NG72UH

6 Departments of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences,

University of Melbourne, Melbourne, Australia

7 Murdoch Children’s Research Institute, Melbourne, Australia

8 Royal Children’s Hospital, Melbourne, Australia

Address correspondence to:

Dr. Samuele Cortese, Academic Unit of Psychology and Clinical and Experimental Sciences (CNS

and Psychiatry) University of Southampton, Highfield Campus, Building 44, Southampton, SO17

1BJ, UK , Phone: +44 (0) 2380599645

E-mail: samuele.cortese@soton.ac.uk

We thank Leon and colleagues for highlighting a topic, namely the role of QEEG in the management of ADHD, that, due to space constraints, we could not address in our review.1

Leon et al. propose to use QEEG for the diagnosis and follow-up of patients with ADHD, and as a prognostic tool. Indeed, in 2013 the US Federal Drug Administration (FDA) approved the marketing of the Neuropsychiatric electroencephalogram (EEG)‐Based ADHD Assessment Aid (NEBA) Health test as an aid in the diagnostic process ADHD. The NEBA test relies upon an EEG‐based measure, called the theta to beta ratio (TBR). However, this approval has been matter of controversy 2, and a number of experts in the field pointed out that there is a lack of solid evidence to support the use of this tool for the diagnosis of ADHD.3  Furthermore, we are not aware of any strong evidence supporting the use of QEEG as a prognostic marker in the treatment of ADHD. While we look forward to further evidence in the field, we would like to stress that the FDA approved the NEBA as an aid for the diagnosis of ADHD. By no means, it should be used as a stand-alone tool replacing clinical judgement and expertise.

**References**

1. Cortese S, Coghill D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward.Evid Based Ment Health. 2018;21(4):173-176.

2. [Stein MA](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Stein%2520MA%255BAuthor%255D&sort=ac&from=/27192956/ac), [Snyder SM](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Snyder%2520SM%255BAuthor%255D&sort=ac&from=/27192956/ac), [Rugino TA](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Rugino%2520TA%255BAuthor%255D&sort=ac&from=/27192956/ac), [Hornig M](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Hornig%2520M%255BAuthor%255D&sort=ac&from=/27192956/ac).Commentary: Objective aids for the assessment of ADHD - further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016). J Child Psychol Psychiatry, 2016, 57 (6):770-1.

3. [Arns M](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Arns%20M%5BAuthor%5D&sort=ac&from=/27090383/ac), [Loo SK](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Loo%20SK%5BAuthor%5D&sort=ac&from=/27090383/ac), [Sterman MB](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Sterman%20MB%5BAuthor%5D&sort=ac&from=/27090383/ac), [Heinrich H](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Heinrich%20H%5BAuthor%5D&sort=ac&from=/27090383/ac), [Kuntsi J](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Kuntsi%20J%5BAuthor%5D&sort=ac&from=/27090383/ac), [Asherson P](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Asherson%20P%5BAuthor%5D&sort=ac&from=/27090383/ac), [Banaschewski T](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Banaschewski%20T%5BAuthor%5D&sort=ac&from=/27090383/ac), [Brandeis D](https://www.ncbi.nlm.nih.gov/m/pubmed/?term=Brandeis%20D%5BAuthor%5D&sort=ac&from=/27090383/ac). Editorial Perspective: How should child psychologists and psychiatrists interpret FDA device approval? Caveat emptor.J Child Psychol Psychiatry 2916;57(5):656-8.